← All trials
NCT04435483
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 22, 2020
- Primary completion
- Jun 25, 2020
- Completion date
- Jun 25, 2020
- First posted
- Jun 17, 2020
- Last posted
- Jun 17, 2020
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- Acerta PharmaCollaborator
- ParexelOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.